Contact Us
Drug Search Results
More Filters [+]

Clazosentan

Alternative Names: clazosentan
Latest Update: 2024-08-09
Latest Update Note: News Article

Product Description

Clazosentan, an endothelin receptor antagonist, has been shown to reduce vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). (Sourced from: https://www.ahajournals.org/doi/10.1161/strokeaha.111.648980)

Mechanisms of Action: ETa Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Idorsia
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Clazosentan

Countries in Clinic: Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Aneurysm|Subarachnoid Hemorrhage

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2018-000241-39

P3

Completed

Aneurysm|Subarachnoid Hemorrhage

2022-11-18

REACT

P3

Completed

Subarachnoid Hemorrhage|Aneurysm

2022-06-13

Recent News Events

Date

Type

Title

08/09/2024

News Article

 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024

05/09/2024

News Article

 Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024

03/13/2024

PubMed

 Comparison of efficacy between clazosentan and fasudil hydrochloride-based management of vasospasm after subarachnoid hemorrhage focusing on older and WFNS grade V patients: a single-center experience in Japan.

02/25/2024

PubMed

 Successful Fluid Management in Respiratory Failure due to Clazosentan Following a Cerebral Aneurysm Clipping: A Case Report.

02/16/2024

PubMed

 Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center.

07/25/2023

News Article

 Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value

07/20/2023

News Article

 Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions